The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 1, might help the stock move higher if these key numbers are better than e ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Au ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has ANIXA BIOSCIENCES INC (ANIX) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.ANIXA BIOSCIENCES INC is a member of our Medical group, which includes 984 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measu ...

scPharmaceuticals, Inc. (SCPH) shares soared 8.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 35.3% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism related to the initial sales uptake of the company's marketed product, Furoscix (furosemide injection), which is indicated for the treatment of edema in adult patients with chronic he ...

Humacyte, Inc. (HUMA) closed the most recent trading day at $2.67, moving -2.2% from the previous trading session. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, added 0.18%. Shares of the company witnessed a gain of 24.66% over the previous month, beating the performance of the Medical sector with its gain of 2.39%, and the S&P 500's gain of 5.71%.Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming ...

BioHarvest Sciences Inc. (BHST) shares soared 5.6% in the last trading session to close at $7.29. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.1% gain over the past four weeks.The sudden price rise can be attributed to positive investor sentiment around the company’s proprietary technology platform for growing plant-based molecules, without the need to grow the underlying plant.This company is expected to post quarterly loss ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Bio-Rad Laboratories (BIO) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 31, might help the stock move higher if these key numbers are better than expecta ...

The market expects Alnylam Pharmaceuticals (ALNY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be ...

The market expects Amicus Therapeutics (FOLD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 31, might help the stock move higher if these key numbers are be ...

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Ju ...